Zim Laboratories promoter acquires 80,000 shares at ₹107.50

1 min read Updated on 17 Jun 2026, 01:37 AM

Reviewed by

Ashish TScanX News Team

AI Summary

Dr. Anwar Daud acquired 80,000 shares from Mr. Zulfiqar Kamal at ₹107.50 per share, increasing his stake to 25.05%. The inter-se transfer is exempt from open offer regulations under SEBI SAST.

*this image is generated using AI for illustrative purposes only.

Zim Laboratories Limited disclosed an inter-se transfer of 80,000 equity shares between promoters, representing 0.15% of the paid-up equity share capital. Dr. Anwar Daud acquired the shares from Mr. Zulfiqar Kamal at a price of ₹107.50 per share. The transaction was executed on or after June 11, 2026, and qualifies for an exemption from making an open offer under Regulation 10(1)(a)(ii) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

The acquisition increased Dr. Anwar Daud's shareholding in the company to 25.05%, comprising 1,34,16,320 shares. Conversely, Mr. Zulfiqar Kamal's holding reduced to 2.08%, equating to 11,15,260 shares post-transaction. The transfer was conducted among the promoters of the company.

The required disclosure regarding the proposed acquisition was filed with the stock exchanges on June 4, 2026, in compliance with Regulation 10(5) of the SEBI SAST Regulations. The shares of Zim Laboratories Limited are listed on the National Stock Exchange of India Limited (NSE) and BSE Limited.

Shareholding Details

The following table outlines the changes in shareholding for the acquirer and the transferor following the transaction:

Entity	Role	Pre-Transaction Shares	Pre-Transaction %	Post-Transaction Shares	Post-Transaction %
Dr. Anwar Daud	Acquirer	1,33,36,320	24.90%	1,34,16,320	25.05%
Mr. Zulfiqar Kamal	Transferor	11,95,260	02.23%	11,15,260	02.08%

The acquisition price was determined to not exceed the limits provided in the proviso to Regulation 10(1)(a) of the SEBI SAST Regulations.

Historical Stock Returns for Zim Laboratories

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+4.79%	+6.63%	+22.61%	+70.13%	+13.33%	+6.51%

Will this consolidation of promoter shares lead to further strategic shifts in Zim Laboratories' management or business direction?

How might the market interpret this transfer regarding Mr. Zulfiqar Kamal's future involvement with the company?

Is Dr. Anwar Daud likely to increase his stake beyond the 25% threshold in the near future?

Read Next Article

Zim Laboratories to meet Florintree Trinex on June 19

0 min read Updated on 16 Jun 2026, 03:18 AM

Reviewed by

Shriram SScanX News Team

Add as a preferred
source on Google

AI Summary

Zim Laboratories Ltd has scheduled a physical one-on-one meeting with Florintree Trinex LLP on June 19, 2026, as part of its investor engagement activities. The company confirmed that no unpublished price sensitive information will be shared during the session. The schedule is subject to change due to exigencies.

*this image is generated using AI for illustrative purposes only.

Zim Laboratories Ltd has scheduled a physical one-on-one meeting with Florintree Trinex LLP on June 19, 2026. The interaction is part of the company's ongoing engagement with investors and analysts, though no unpublished price sensitive information will be disclosed during the session.

The meeting details were disclosed in a filing submitted to BSE Limited and National Stock Exchange of India Limited on June 15, 2026. The company confirmed that the schedule is subject to change due to exigencies.

The disclosure was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Piyush Siddheshwar Nikhade, Company Secretary and Compliance Officer, signed the filing on behalf of Zim Laboratories Limited.